Article -> Article Details

The global cancer/tumor profiling market is witnessing robust growth, fueled by advancements in precision medicine and the increasing prevalence of cancer worldwide. Valued at USD 12.47 billion in 2024, the market is projected to reach USD 26.29 billion by 2033, growing at a CAGR of 8.21% during 2025-2033. Key drivers include the rising adoption of personalized treatment approaches, technological innovations in genomic and proteomic profiling, and the growing demand for biomarker-based diagnostics. North America currently leads the market, holding a significant share of over 42.8% in 2024 .

Study Assumption Years

• Base Year: 2024
  
  

• Historical Years: 2019-2024
  
  

• Forecast Years: 2025-2033
  
  

Cancer/Tumor Profiling Market Key Takeaways

• Market Size & Growth: The market was valued at USD 12.47 billion in 2024 and is expected to reach USD 26.29 billion by 2033, exhibiting a CAGR of 8.21% during 2025-2033 .
  
  

• Regional Dominance: North America holds the largest market share, accounting for over 42.8% in 2024, driven by advanced healthcare infrastructure and high adoption of precision medicine.
  
  

• Cancer Type Leadership: Breast cancer leads the market due to its high global prevalence and increasing adoption of personalized medicine in oncology.
  
  

• Technological Advancements: Next-Generation Sequencing (NGS) is a prominent technology, enabling comprehensive genomic analysis for identifying cancer mutations and biomarkers.
  
  

• Technique Utilization: Genomics is the largest technique segment, playing a central role in understanding the genetic basis of cancer.
  
  

• Application Focus: Personalized medicine is a significant application area, offering treatments based on individual genetic and molecular profiles.
  
  

• Emerging Markets: Asia Pacific is experiencing substantial growth due to rising cancer incidence and increasing adoption of advanced diagnostic technologies.

Request for a sample copy of this report : https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample

Market Growth Factors

1. Technological Developments in Proteomic and Genomic Profiling

Technological developments in genomic and proteomic profiling define the cancer/tumour profiling sector to a large extent. Advancements in Next- Generation Sequencing (NGS) have transformed the capacity to perform thorough genomic studies, allowing the detection of cancer mutations and biomarkers with great accuracy. These technologies enable individualized diagnostics and therapies, hence enabling targeted treatments that enhance patient results. The demand for NGS in cancer profiling studies is driven by its growing use in companion diagnostics as well as in clinical oncology.

2. Growing cancer prevalence and demand for customized treatment

One of the main reasons fueling the expansion of the market for cancer/tumor profiling is the worldwide rise in cancer incidence. Better diagnostic and treatment alternatives are urgently needed given almost 20 million instances diagnosed worldwide in 2022 and projections suggesting an increase to 35 million by 2050. This trend emphasizes the need of tumor profiling in creating personalized treatments and raising survival rates. The need for sophisticated techniques in tumor profiling is being driven by the emphasis on precise and certain diagnostic solutions towards the improvement of patient outcomes.

3. Research Financing in Oncology from Government

The growth of the market for cancer/tumor profiling depends critically on government support and private investments in oncology research. The UK Government, for example, has vowed to raise its overall research and development (RandD) expenditure to 2.4% of GDP by 2027, stressing the increasing emphasis on innovation in cancer diagnostics and treatments. These investments drive market expansion by both making precision medicine more widely available and spurring ground-breaking developments in tailored cancer therapy.

.

Market Segmentation

By Cancer Type:

• Breast Cancer: Leads the market due to high global prevalence and increasing adoption of personalized medicine in oncology.
  
  

• Lung Cancer: Significant segment driven by the need for early detection and targeted therapies.
  
  

• Colorectal Cancer: Growing focus on early diagnosis and personalized treatment approaches.
  
  

• Prostate Cancer: Advancements in profiling techniques aiding in better management and treatment.
  
  

• Melanoma Cancer: Increasing utilization of tumor profiling for targeted therapy development.
  
  

• Others: Includes various other cancer types where profiling is becoming increasingly relevant.
  
  

By Technology:

• Next-Generation Sequencing (NGS): Enables comprehensive genomic analysis for identifying cancer mutations and biomarkers.
  
  

• Polymerase Chain Reaction (PCR): Highly sensitive and specific in detecting genetic mutations and alterations.
  
  

• Immunohistochemistry (IHC): Crucial for identifying biomarkers for targeted therapies, improving patient outcomes.
  
  

• In-Situ Hybridization (ISH): Valuable tool in oncology research and diagnostics for discovering therapeutic targets.
  
  

• Microarray: Facilitates the analysis of gene expression patterns and identification of biomarkers.
  
  

• Others: Includes various other technologies contributing to tumor profiling advancements.
  
  

By Technique:

• Genomics: Plays a central role in understanding the genetic basis of cancer, leading the market with around 39.8% share in 2024.
  
  

• Proteomics: Involves the large-scale study of proteins, essential for understanding cancer biology.
  
  

• Epigenetics: Focuses on heritable changes in gene expression without altering the DNA sequence, important in cancer development.
  
  

• Metabolomics: Studies metabolic changes in cancer cells, aiding in biomarker discovery and therapeutic targeting.
  
  

By Application:

• Personalized Medicine: Provides treatment based on an individual's genetic and molecular profile, improving therapy effectiveness.
  
  

• Diagnostics: Accurate identification of cancer type and stage via advanced tumor profiling techniques.
  
  

• Biomarker Discovery: Focuses on identifying molecular markers associated with cancer development and progression.
  
  

• Prognostics: Used to predict cancer progression, survival rate, and possible treatment response through tumor profiling.
  
  

• Others: Includes various other applications where tumor profiling is becoming increasingly relevant.
  
  

Breakup by Region:

• North America (United States, Canada)

• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

Regional Insights

North America dominates the cancer/tumor profiling market, accounting for over 42.8% of the global share in 2024. This leadership is attributed to advanced healthcare infrastructure, high adoption of precision medicine, and substantial investments in oncology research. The region benefits from the widespread availability of advanced diagnostic technologies such as NGS and PCR, along with a strong presence of key market players. Rising cancer prevalence and government initiatives to support cancer screening and biomarker research further propel market growth .

Recent Developments & News

The cancer/tumor profiling market has seen several significant developments:

• In October 2024, Illumina partnered with AstraZeneca to develop innovative NGS-based companion diagnostics, enhancing oncology-related solutions.
  
  

• September 2024 saw Thermo Fisher launching the Oncomine Comprehensive Assay Plus, a targeted NGS tool designed to detect essential mutations in solid tumors.
  
  

• In November 2023, Illumina unveiled the latest version of its liquid biopsy assay for genomic profiling, the TruSight Oncology 500 ctDNA v2, providing comprehensive genomic insights from blood samples.
  
  

• May 2023 marked Pfizer's partnership with Thermo Fisher Scientific in a strategic collaboration aimed at increasing the availability of NGS-based testing for lung and breast cancer patients across more than 30 countries .
  
  

Key Players

• Abbott Laboratories

• Becton Dickinson and Company

• Caris Life Sciences

• Exact Sciences Corporation

• F. Hoffmann-La Roche Ltd

• Hologic Inc.

• HTG Molecular Diagnostics Inc.

• Illumina Inc.

• Laboratory Corporation of America Holdings

• NeoGenomics Laboratories

• Qiagen N.V.

• Siemens AG

• Sysmex Corporation

Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5231&flag=C

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.